Tissue Repository for Studies of Myasthenia Gravis
| Status: | Enrolling by invitation |
|---|---|
| Conditions: | Neurology, Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/25/2018 |
| Start Date: | August 2015 |
| End Date: | August 2019 |
This is a study during which the investigators collect plasma and cells from patients with
myasthenia gravis for the purpose of finding new antibodies.
myasthenia gravis for the purpose of finding new antibodies.
This is a bio-specimen collection study. The investigators will collect plasma and peripheral
lymphocytes. Plasma will be collected either when the patient undergoes plasma exchange, a
decision independent of this study, or through a scheduled blood draw.
Patient plasma will be screened for novel antibodies which may cause myasthenia gravis.
Subjects that are found to be positive for candidate antigens for myasthenia gravis will have
a clinical evaluation which will consist of several disease rating scales will be performed
(QMG score, MG-composite, Myasthenia Gravis Foundation of America (MGFA) clinical
classification, MG-Quality of Life (QOL)15, MGFA Therapy Status).
lymphocytes. Plasma will be collected either when the patient undergoes plasma exchange, a
decision independent of this study, or through a scheduled blood draw.
Patient plasma will be screened for novel antibodies which may cause myasthenia gravis.
Subjects that are found to be positive for candidate antigens for myasthenia gravis will have
a clinical evaluation which will consist of several disease rating scales will be performed
(QMG score, MG-composite, Myasthenia Gravis Foundation of America (MGFA) clinical
classification, MG-Quality of Life (QOL)15, MGFA Therapy Status).
Inclusion Criteria:
- 18 years of age or older.
- Clinical Diagnosis of MG with supporting evidence either from antibody testing,
repetitive nerve stimulations study (RNS) or Single Fiber Electromyography (EMG)
(SFEMG).
Exclusion Criteria:
- Significant medical condition that would make participation in diagnostic and research
part of evaluation impossible or risky. Acute or unstable medical condition.
- Inability to provide informed consent, either directly or via appointed power of
attorney.
- Unwillingness to consent for collection of biological samples or their
cryopreservation.
- Unable to provide evidence of previous antibody testing or neurophysiology confirming
the diagnosis of Myasthenia Gravis.
- Any bleeding disorder that would prevent or present any danger during blood
extraction.
We found this trial at
1
site
Johns Hopkins Hospital Patients are the focus of everything we do at The Johns Hopkins...
Click here to add this to my saved trials
